Premium
Significance of serum amyloid a on the prognosis in patients with renal cell carcinoma
Author(s) -
Kimura Motohiko,
Tomita Yoshihiko,
Imai Tomoyuki,
Saito Toshihiro,
Katagiri Akiyoshi,
OharaMikami Yukie,
Matsudo Takayuki,
Takahashi Kota
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20011015)92:8<2072::aid-cncr1547>3.0.co;2-p
Subject(s) - medicine , serum amyloid a , renal cell carcinoma , serum amyloid a protein , erythrocyte sedimentation rate , carcinoma , univariate analysis , gastroenterology , interleukin 6 , acute phase protein , cancer , oncology , c reactive protein , pathology , multivariate analysis , inflammation
BACKGROUND Evidence of systemic inflammation, i.e., elevation of serum C–reactive protein, interleukin‐6, and/or the erythrocyte sedimentation rate, is correlated to poorer prognosis of patients with renal cell carcinoma (RCC). Serum amyloid A (SAA) has been recognized mainly as acute‐phase reactant. METHODS Serum SAA from 72 patients with RCC were examined. Thirty‐eight of 72 patients with RCC had elevated SAA compared with 17 healthy donors. RESULTS The disease specific survival rate was significantly lower in the elevated SAA group, and SAA level was shown to be an independent prognostic factor by univariate and multivariate analysis. CONCLUSIONS Evaluation of serum SM level in RCC patients may be a useful prognostic indicator. Cancer 2001;92:2072–5. © 2001 American Cancer Society.